- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06615999
Treatment Reality of Tension Band Wiring and Locked Plate Fixation of the Olecranon
Treatment Reality of Tension Band Wiring and Locked Plate Fixation of the Olecranon - Analysis of Complications, Risk Profiles and Trends
The incidence of the olecranon fracture (OF) in adults is around 12 per 100,000 inhabitants per year.1 The anatomical shape of the proximal ulna is largely responsible for the stabilization of the humeroulnar joint and reconstruction is therefore obligatory, but often challenging. Surgical treatment of the olecranon fracture is performed using tension band wiring (TBW) or locking plate fixation (LPF) osteosynthesis. It is not yet clear, which procedure is superior for a specific patient. In future, an individualized and objectified assessment of expected general and fracture-specific complications should enable the treatment to be individually adapted to the patient's risk profile. This shall prevent complications, unnecessary treatments, and treatment costs. In the project presented here, the reality of care for surgically treated patients with olecranon fractures will be analyzed using routine data collected by the BARMER health insurance fund.
The aim of the study is to analyze differences in the outcome of patients with an olecranon fracture treated with TBW compared to LPF and to identify independent risk factors for unfavorable course.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Inpatient coded diagnosis of olecranon fracture (ICD S52.01)
Exclusion Criteria:
- Incomplete basic information
- Incomplete insurance status within two years before index
- Previous treatment of olecranon fracture
- Unclear treatment of olecranon fracture
- Age < 18 years
- Coded polytrauma
- Bone tumors/ bone metastasis
- Both sides injured or missing information of surgery side
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Locking Plate fixation for simple fractured OFs (sLPF)
Patients allocated to this treatment group received a locking plate fixation after the first coded diagnosis of simple fractured OF.
|
OPS 5-793.k7
|
|
Locking Plate fixation for multi-fragmented OFs (LPF)
Patients allocated to this treatment group received a locking plate fixation after after the first coded diagnosis of multi-fragmented OF.
|
OPS 5-794.k7
|
|
Tension band wiring for simple fractured OFs (sTBW)
Patients allocated to this treatment group received a tension band wiring fixation after the first coded diagnosis of simple fractured OF.
|
OPS 5-793.27
|
|
Tension band wiring for multi-fragmented OFs (TBW)
Patients allocated to this treatment group received a tension band wiring fixation after the first coded diagnosis of multi-fragmented OF.
|
OPS 5-794.17
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Revision
Time Frame: up to 5 years
|
Time from surgery to revision defined above.
|
up to 5 years
|
|
Implant removal (only)
Time Frame: up to 5 years
|
|
up to 5 years
|
|
Surgical complications (surgical complications)
Time Frame: up to 5 years
|
Time from surgery of olecranon fracture to surgical complications, with death being considered as a competing risk event.
|
up to 5 years
|
|
In-hospital surgical complication rate (IH-SC)
Time Frame: through hospital stay, an average of 10 days
|
surgical complication after surgery during index hospitalization (yes/no)
|
through hospital stay, an average of 10 days
|
|
In-hospital implant-associated complications (IH-IAC)
Time Frame: through hospital stay, an average of 10 days
|
In-hospital implant-associated complications after surgery during index hospitalization
|
through hospital stay, an average of 10 days
|
|
In-hospital non-implant associated complications (IH-non-IAC)
Time Frame: through hospital stay, an average of 10 days
|
Non-in-hospital implant-associated complications after surgery during index hospitalizationi
|
through hospital stay, an average of 10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: up to 5 years
|
|
up to 5 years
|
|
30-day mortality
Time Frame: 30 days
|
|
30 days
|
|
Major adverse events (MAE)
Time Frame: up to 5 years
|
Time from surgery to resuscitation, cardiac arrest, myocardial infarction, stroke, acute renal failure, acute liver failure, acute respiratory distress syndrome, sepsis or death from any case.
|
up to 5 years
|
|
Thromboembolic events
Time Frame: up to five years
|
Time from surgery to a thromboembolic event or death of any cause.
|
up to five years
|
|
Minor outpatient complication
Time Frame: up to five years
|
Time from discharge to minor outpatient complications, with death being considered as a competing risk event.
|
up to five years
|
|
Length of hospital stay during index
Time Frame: an average of 10 days
|
Days of hospitalization (from admission to last discharge with index case series)
|
an average of 10 days
|
|
Charges during index
Time Frame: an average of 10 days
|
Sum of charges of all cases of the index case series
|
an average of 10 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Olecranon TBW vs. LPF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.